MTCH
37
-2
SE
52
-2
TAP
47
-4
ADT
53
2
PDCO
40
2
HOG
27
-2
GD
50
-2
MAS
58
-4
DFS
70
5
MMM
30
-3
QCOM
53
-7
MSFT
54
-3
NEM
28
-4
URI
59
-3
O
35
-2
YUM
39
-3
COF
64
2
NRG
62
-2
EMC
62
-6
MCHP
42
-7
MTCH
37
-2
SE
52
-2
TAP
47
-4
ADT
53
2
PDCO
40
2
HOG
27
-2
GD
50
-2
MAS
58
-4
DFS
70
5
MMM
30
-3
QCOM
53
-7
MSFT
54
-3
NEM
28
-4
URI
59
-3
O
35
-2
YUM
39
-3
COF
64
2
NRG
62
-2
EMC
62
-6
MCHP
42
-7
Financhill
Back

Autolus Therapeutics PLC 10K Form

Sell
50

AUTL
Autolus Therapeutics PLC

Last Price:
3.37
Seasonality Move:
3.24%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive AUTL News And Ratings

See the #1 stock for the next 7 days that we like better than AUTL

AUTL Financial Statistics

Sales & Book Value

Annual Sales: $1.7M
Cash Flow: $-51.92M
Price / Cash Flow: 0
Annual Sales: $1.98
Price / Book: 2.01

Profitability

EPS (TTM): -1.17000
Net Income (TTM): $-233.98M
Gross Margin: --
Return on Equity: 0%
Return on Assets: 0%

Autolus Therapeutics PLC Earnings Forecast

Key Autolus Therapeutics PLC Financial Ratios

  • The Research & Development expenses have been 7,684.39% of Revenue.
  • The Interest Expense is -21.63% of Operating Income.
  • The Net Earning history of AUTL is -12,272.26% of Total Revenues.
  • Per Share Earnings over the last 8 years have been positive in 5 years.

Autolus Therapeutics PLC Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: AUTL
CUSIP: 05280R
Website: autolus.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 0
Quick Ratio: 0

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

AUTL Technical Analysis vs Fundamental Analysis

Sell
50
Autolus Therapeutics PLC (AUTL) is a Sell

Is Autolus Therapeutics PLC a Buy or a Sell?